Track topics on Twitter Track topics that are important to you
MorphoSys and Galapagos are halting development of MOR106—an atopic dermatitis candidate the companies licensed to Novartis last year for potentially more than $1 billion—after an interim futility analysis of a Phase II trial showed the drug was unlikely to meet the study’s primary endpointNEXT ARTICLE
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...